JP2023515190A5 - - Google Patents

Info

Publication number
JP2023515190A5
JP2023515190A5 JP2022551573A JP2022551573A JP2023515190A5 JP 2023515190 A5 JP2023515190 A5 JP 2023515190A5 JP 2022551573 A JP2022551573 A JP 2022551573A JP 2022551573 A JP2022551573 A JP 2022551573A JP 2023515190 A5 JP2023515190 A5 JP 2023515190A5
Authority
JP
Japan
Prior art keywords
cancer
apc
inhibitor
optionally
tdo2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022551573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515190A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/019989 external-priority patent/WO2021174058A1/en
Publication of JP2023515190A publication Critical patent/JP2023515190A/ja
Publication of JP2023515190A5 publication Critical patent/JP2023515190A5/ja
Pending legal-status Critical Current

Links

JP2022551573A 2020-02-27 2021-02-26 Ａｐｃ欠損がんの治療のための方法および組成物 Pending JP2023515190A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062982561P 2020-02-27 2020-02-27
US62/982,561 2020-02-27
PCT/US2021/019989 WO2021174058A1 (en) 2020-02-27 2021-02-26 Methods and compositions for treatment of apc-deficient cancer

Publications (2)

Publication Number Publication Date
JP2023515190A JP2023515190A (ja) 2023-04-12
JP2023515190A5 true JP2023515190A5 (https=) 2024-02-27

Family

ID=77490376

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022551573A Pending JP2023515190A (ja) 2020-02-27 2021-02-26 Ａｐｃ欠損がんの治療のための方法および組成物

Country Status (10)

Country Link
US (1) US20230250433A1 (https=)
EP (1) EP4110923A4 (https=)
JP (1) JP2023515190A (https=)
KR (1) KR20230004458A (https=)
CN (1) CN115515636A (https=)
AU (1) AU2021226012A1 (https=)
BR (1) BR112022016903A2 (https=)
CA (1) CA3172886A1 (https=)
MX (1) MX2022010644A (https=)
WO (1) WO2021174058A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025160462A1 (en) * 2024-01-24 2025-07-31 Iterion Therapeutics Inc. Methods for treatment of hepatocellular carcinoma
CN119236084A (zh) * 2024-11-06 2025-01-03 上海市皮肤病医院 一种tdo2抑制剂在制备治疗皮肤鳞状细胞癌药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010008427A1 (en) * 2008-04-11 2010-01-21 Ludwig Institute For Cancer Research Ltd. Tryptophan catabolism in cancer treatment and diagnosis
EP3334733A1 (en) * 2015-08-10 2018-06-20 Pfizer Inc 3-indol substituted derivatives, pharmaceutical compositions and methods for use
CN107021929A (zh) * 2016-01-29 2017-08-08 苏州国匡医药科技有限公司 一类新型ido抑制剂、制备方法、药物组合物及其用途
CN110791565B (zh) * 2019-09-29 2021-09-03 浙江大学 一种用于ii期结直肠癌复发预测的预后标记基因及随机生存森林模型

Similar Documents

Publication Publication Date Title
Xu et al. CXCR4 overexpression is correlated with poor prognosis in colorectal cancer
Schneider et al. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer
Li et al. S100A16 induces epithelial-mesenchymal transition in human PDAC cells and is a new therapeutic target for pancreatic cancer treatment that synergizes with gemcitabine
Liu et al. Role of circular RNAs in cancer therapy resistance
Xiao et al. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
Tanaka et al. Potential Benefits of Bevacizumab Combined with Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation
Liu et al. CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy
JP2023515190A5 (https=)
Piegeler et al. Anesthesia and colorectal cancer–the perioperative period as a window of opportunity?
Chen et al. Knockdown of DDX46 suppresses the proliferation and invasion of gastric cancer through inactivating Akt/GSK-3β/β-catenin pathway
Guastafierro et al. The influence of breast cancer on the distribution of cherry angiomas on the anterior thoracic wall: a case series study
Denduluri et al. Circulating biomarkers of bevacizumab activity in patients with breast cancer
Zhang et al. TLR4 inhibited autophagy by modulating PI3K/AKT/mTOR signaling pathway in Gastric cancer cell lines
Xinzhe et al. Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2021.
Thomas et al. Head and neck squamous cell carcinoma
Yuxian et al. Paired-like homeodomain transcription factor 2 strengthens chemoresistance in colorectal cancer by activating the Wnt/β-catenin axis.
Lorenzen et al. 1502TiP Paclitaxel+ ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs-RAMOS, a randomized phase II trial of the German Gastric Group of the AIO
Ma Exosomal LINC00174 facilitates epithelial-mesenchymal transition in residual hepatocellular carcinoma after insufficient radiofrequency ablation by regulating c-JUN/MYCBP/c-Myc axis
Giunashvili 48P Non-steroid anti-inflammatory treatment enhances the efficacy of modulated electro hyperthermia on triple-negative breast cancer and melanoma cancer models in vivo
Alhajlah The molecular mechanisms of various long non-coding RNA (lncRNA) in human lung tumors: Shedding light on the molecular mechanisms
Zaboli et al. HER2 Amplification in Non-Mutant RAS Status in Patients with Metastatic Colorectal Cancer and the 2-Year Survival Rate
Orndorff et al. EXTH-50. ACUTE AND LONG-TERM RESPONSES TO QUISINOSTAT TREATMENT IN PDX MODELS OF GLIOBLASTOMA
Lavy Shahaf et al. P04. 17 Cancer cell lines response to tumor treating fields: results of a meta-analysis
Scarlato et al. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from the phase II nITRO trial
He et al. Overexpression of CSRP1 Suppresses Cell Viability and Enhances the Anti-Cancer Effects of Anti-PD-L1 Therapy in Renal Cell Carcinoma